Annual report
4078.TEDINET S100R306
Period2022-04-01 → 2023-03-31
Filed2023-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥83.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥80.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥84.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥87.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥89.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥4.4bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥7.5bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥4.9bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥8.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.0bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.2bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.6bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.0bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥9.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥6.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.5bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.6bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥7.1bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥128.0bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥123.9bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥123.0bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥121.6bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥120.1bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥43.3bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥41.2bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥84.7bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥82.7bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥79.3bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥81.5bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥80.3bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥12.4bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.8bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥12.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.2bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.1bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥11.2bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥773m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.4bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥5.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.7bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥68m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥64m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥144.85 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥407.06 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-166.58 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥150.84 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥210.34 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4,970.11 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,875.69 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,502.33 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,657.04 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,598.89 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 62.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.6% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.3% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 2.9% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.7% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | -3.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.6% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 2,013 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 2,024 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 2,009 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 2,003 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 1,964 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥42.8bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥41.1bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥34.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥37.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥40.6bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥285m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥2.6bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.1bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.8bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥943m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.0bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.2bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.6bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥5.2bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.4bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥4.6bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | −¥4.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.0bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥87.8bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥87.6bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥88.8bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥88.7bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥84.6bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥35.0bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥35.0bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥52.8bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥52.6bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥51.6bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥55.5bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥55.3bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.9bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥6.9bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥85.72 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥278.97 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-245.57 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.38 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥114.76 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥75 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,259.43 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,253.05 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,064.29 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,297.38 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,293.74 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 60.1% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.1% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.5% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.4% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.6% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -7.7% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 17,000,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 769 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 773 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 774 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 776 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 768 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 57
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥64m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥146m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥1.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥1.0bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥13.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥2.2bn |
| Chemicalreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥3.3bn |
| Chemicalreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥4.0bn |
| Chemicalreportable segment | employees | at 2023-03-31 | 1685 pure |
| Chemicalreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥76.7bn |
| Chemicalreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥76.0bn |
| Chemicalreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥757m |
| Chemicalreportable segment | segment assets | at 2023-03-31 | ¥100.8bn |
| Chemicalreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥6.4bn |
| Medicine And Healthcarereportable segment | capex | 2022-04-01 → 2023-03-31 | ¥207m |
| Medicine And Healthcarereportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥237m |
| Medicine And Healthcarereportable segment | employees | at 2023-03-31 | 271 pure |
| Medicine And Healthcarereportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥8.1bn |
| Medicine And Healthcarereportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥7.9bn |
| Medicine And Healthcarereportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥270m |
| Medicine And Healthcarereportable segment | segment assets | at 2023-03-31 | ¥13.6bn |
| Medicine And Healthcarereportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥272m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥3.5bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥4.3bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥84.9bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥83.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥1.0bn |
| —segment total | segment assets | at 2023-03-31 | ¥114.4bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥6.6bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥197m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥153m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥1.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥1.7bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥13.9bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥2.1bn |
| Chemicalreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| Chemicalreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥4.0bn |
| Chemicalreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥73.7bn |
| Chemicalreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥72.2bn |
| Chemicalreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥1.4bn |
| Chemicalreportable segment | segment assets | at 2022-03-31 | ¥96.5bn |
| Chemicalreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥9.2bn |
| Medicine And Healthcarereportable segment | capex | 2021-04-01 → 2022-03-31 | ¥794m |
| Medicine And Healthcarereportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥228m |
| Medicine And Healthcarereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥8.2bn |
| Medicine And Healthcarereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥7.9bn |
| Medicine And Healthcarereportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥292m |
| Medicine And Healthcarereportable segment | segment assets | at 2022-03-31 | ¥13.5bn |
| Medicine And Healthcarereportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥418m |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥3.4bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥4.2bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥81.8bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥80.1bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥1.7bn |
| —segment total | segment assets | at 2022-03-31 | ¥110.0bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥9.6bn |
| Chemicalreportable segment | employees | at 2023-03-31 | 712 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,685
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents | Prior1YearInstant | 10549000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 10549000000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 12188000000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 16 | |
| Discounted trade notes receivable | Prior1YearInstant | 0 | JPY |
| Discounted trade notes receivable | CurrentYearInstant | － | JPY |
| Notes receivable trade | Prior1YearInstant | 5931000000 | JPY |
| Notes receivable trade | CurrentYearInstant | 5454000000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 23976000000 | JPY |
| Accounts receivable trade | CurrentYearInstant | 22101000000 | JPY |
| Haulage expenses sga | Prior1YearDuration | 2160000000 | JPY |
| Haulage expenses sga | CurrentYearDuration | 2037000000 | JPY |
| Employees salaries and allowances sga | Prior1YearDuration | 4107000000 | JPY |
| Employees salaries and allowances sga | CurrentYearDuration | 4168000000 | JPY |
| Provision for bonuses sga | Prior1YearDuration | 896000000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 905000000 | JPY |
| Retirement benefit expenses sga | Prior1YearDuration | 288000000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | 329000000 | JPY |
| Provision for directors bonuses sga | Prior1YearDuration | 134000000 | JPY |
| Provision for directors bonuses sga | CurrentYearDuration | 95000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration | 134000000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration | 136000000 | JPY |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period | Prior1YearDuration | 2376000000 | JPY |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period | CurrentYearDuration | 2674000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 72243000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 7892000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 80135000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 80135000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 1421000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 292000000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | 1713000000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | -1713000000 | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 73664000000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 8185000000 | JPY |
| Net sales | Prior1YearDuration_ReportableSegmentsMember | 81849000000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | -1713000000 | JPY |
| Net sales | Prior1YearDuration | 80135000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 9190000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 418000000 | JPY |
| Operating income | Prior1YearDuration_ReportableSegmentsMember | 9608000000 | JPY |
| Operating income | Prior1YearDuration_ReconcilingItemsMember | -2114000000 | JPY |
| Operating income | Prior1YearDuration | 7494000000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 96494000000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 13529000000 | JPY |
| Assets | Prior1YearInstant_ReportableSegmentsMember | 110023000000 | JPY |
| Assets | Prior1YearInstant_ReconcilingItemsMember | 13896000000 | JPY |
| Assets | Prior1YearInstant | 123919000000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 3952000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |